Skip to main content
OpenTrials
Completed

NCT Number: NCT06620315

Comparison Between Primary and Secondary Implant Stability of Hybrid Versus Resorbable Blast Media (RBM) Surfaces Using Resonance Frequency Analysis

• To compare primary stability (during initial loading of implant) and secondary stability (after 12 weeks of implant loading) which are denoted as ISQ value of Hybrid (DIO UFII) versus Resorbable blast media (RBM) (Osstem TSII) implant surfaces.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Prosthodontics, Institute of Dentistry/CMH Lahore Medical College.

Lahore, Punjab Province, 41000, Pakistan

About this study

An approval from the hospital ethical committee will be obtained for this study. As a protocol all patients presenting to Institute of Dentistry, CMH Lahore Medical College will be examined in general OPD and those patients who fulfill the inclusion and exclusion criteria will be referred to Prosthodontics department. After history, complete oral examination and informed consent. Patients will be divided into two groups by lottery method; In Group 1 Hybrid (sand blasted acid etched implants) will be place. In Group 2 Resorbable Blast Media (RBM) implant surfaces will be placed. On the basis of randomized study the patients will be selected for the study to measure implant primary stability with a resonance frequency analyzer at the time of initial loading of implant, starting with an assessment immediately following implant placement with insertion torque of 30 Ncm and then secondary stability at 12 weeks post operatively by using Ostell Mentor. This instrument on each implant by inserting a standardized abutment (Smartpeg) of fixed length into each implant. The transducer probe (Osstell mentor probe) will be held so that the probe tip was aimed at the small magnet on top of the Smartpeg at a distance of 2-3 mm in both the buccal and lingual directions, and the mean of these measurements will then be calculated. The probe will be held still during the pulsing time until the instrument beeped and the displayed the ISQ value. ISQ1 will be evaluated immediately during initial implant loading which will be primary stability and ISQ2 will be evaluated after 12 weeks of implant placement when implant is properly osseointegrated, which will be secondary stability of an implant.

The implant fixtures will be DIO UF II for the Hybrid implants and the Osstem TSII plus system for the RBM implants. Data would be stratified for age, gender and implant site to address the effect modifiers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • o Age between 20 to 50 years.
  • Both male and female patients will be selected.
  • Patients suitable for implant restorations on CBCT will be diagnosed by;
  • Bone height (minimum of 12mm)
  • Bone width (minimum of 5mm)
  • Proximity with vital structures (nerves, blood vessels)

Exclusion criteria

  • o Patients with diabetes, Parkinson's disease, myasthenia gravis and bulbar palsy
  • Diseases with either a strong connection to emotional stress or impairing mental health like depression, anxiety, sleeping disorder on history examination.
  • Patients with poor oral hygiene.
  • Patients with parafunctional habits of severe clenching habit, bruxism.
  • Heavy smokers
  • Patients who had undergone radiotherapy or chemotherapy.
  • Patients with osteoarthritis, osteoporosis.
  • Patients taking bisphosphonates

Treatment and study plan

RBM

Combination Product

Resorbable Blast Media (RBM) implant surfaces can enhance osseointegration and implant stability

sand blasted implant

Combination Product

sand blasted implant

Primary outcomes

  1. Primary Stability

    Time frame: up to 3 months

    absence of clinically detectable implant mobility

Secondary outcomes

  1. Secondary Stability

    Time frame: 3 months

    absence of clinically detectable implant mobility

Sponsors and collaborators

Lead sponsor

Shaheed Zulfiqar Ali Bhutto Medical University

Other

Registry information

Acronym: IMPLANTSTABIL

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 1, 2024
Registry last updated
Oct 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.